<DOC>
	<DOC>NCT02992652</DOC>
	<brief_summary>- The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis. - 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.</brief_summary>
	<brief_title>Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis</brief_title>
	<detailed_description>A diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Patients who were going to be subjected to ERCP due to different causes Patients with clinically evident acute pancreatitis or hyperamylesemia (â‰¥150 IU/L) before the procedure. Current or recent use of allopurinol (within the last 48 hours). Hypersensitivity to allopurinol or hydrosoluble contrast solutions. Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid. NSAIDS intake within a week prior to assessment. Previous endoscopic or surgical sphincterotomy. Those with severe comorbid conditions. Female patients with a known or suspected pregnancy and/or lactation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>